Skip to main content

Advertisement

SpringerLink
Log in

Life-threatening bleeding under vitamin K antagonists in spite of an INR in the therapeutic range

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Schulman S, Beyth RJ, Kearon C, Levine MN (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest 133(6 Suppl):257S–298S. doi:10.1378/chest.08-0674

    Article  PubMed  CAS  Google Scholar 

  2. Salem DN, O’Gara PT, Madias C, Pauker SG (2008) Valvular and structural heart disease: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest 133(6 Suppl):593S–629S. doi:10.1378/chest.08-0724

    Article  PubMed  Google Scholar 

  3. Chu K, Wu SM, Stanley T, Stafford DW, High KA (1996) A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest 98(7):1619–1625. doi:10.1172/JCI118956

    Article  PubMed  CAS  Google Scholar 

  4. Oldenburg J, Quenzel EM, Harbrecht U, Fregin A, Kress W, Muller CR, Hertfelder HJ, Schwaab R, Brackmann HH, Hanfland P (1997) Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol 98(1):240–244

    Article  PubMed  CAS  Google Scholar 

  5. Jorgensen MJ, Cantor AB, Furie BC, Brown CL, Shoemaker CB, Furie B (1987) Recognition site directing vitamin K-dependent gamma-carboxylation resides on the propeptide of factor IX. Cell 48(2):185–191. doi:0092-8674(87)90422-3[pii]

    Article  PubMed  CAS  Google Scholar 

  6. Furie B, Furie BC (1988) The molecular basis of blood coagulation. Cell 53(4):505–518

    Article  PubMed  CAS  Google Scholar 

  7. Aegerter C, Fontana S, Fux C, Demarmels Biasiutti F (2003) Life threatening bleeding under adequate oral anticoagulation. Cases 4a, b. Hamostaseologie 23(3):113–116. doi:10.1267/Hamo0303011303030113

    PubMed  Google Scholar 

  8. Baker P, Clarke K, Giangrande P, Keeling D (2000) Ala-10 mutations in the factor IX propeptide and haemorrhage in a patient treated with warfarin. Br J Haematol 108(3):663

    Article  PubMed  CAS  Google Scholar 

  9. Harbrecht U, Oldenburg J, Klein P, Weber D, Rockstroh J, Hanfland P (1998) Increased sensitivity of factor IX to phenprocoumon as a cause of bleeding in a patient with antiphospholipid antibody associated thrombosis. J Intern Med 243(1):73–77

    Article  PubMed  CAS  Google Scholar 

  10. Holbro A, Marbet GA, Tran TH, Oldenburg J, Friesewinkel O, Tsakiris DA (2010) Prosthetic heart valves and rare hypersensitivity to vitamin K antagonists resulting from factor IX mutation: how to manage anticoagulation? Haemophilia 16(1):187–189. doi:10.1111/j.1365-2516.2009.02115.x

    Article  PubMed  CAS  Google Scholar 

  11. Kristensen SR (2002) Warfarin treatment of a patient with coagulation factor IX propeptide mutation causing warfarin hypersensitivity. Blood 100(7):2676–2677

    Article  PubMed  CAS  Google Scholar 

  12. Lammle B (2003) Clinical problems with oral anticoagulation–3 case reports. Ther Umsch 60(1):63–66

    Article  PubMed  CAS  Google Scholar 

  13. Neuhaus T, Hertfelder HJ, Hess L, Oldenburg J, Walger P, Vetter H (2001) An uncommon cause of severe soft tissue bleeding during phenprocoumon treatment. Dtsch Med Wochenschr 126(25–26):754–756. doi:10.1055/s-2001-15099

    Article  PubMed  CAS  Google Scholar 

  14. Oldenburg J, Kriz K, Wuillemin WA, Maly FE, von Felten A, Siegemund A, Keeling DM, Baker P, Chu K, Konkle BA, Lammle B, Albert T (2001) Genetic predisposition to bleeding during oral anticoagulant therapy: evidence for common founder mutations (FIXVal-10 and FIXThr-10) and an independent CpG hotspot mutation (FIXThr-10). Thromb Haemost 85(3):454–457

    PubMed  CAS  Google Scholar 

  15. Quenzel EM, Hertfelder HJ, Oldenburg J (1997) Severe bleeding in two patients due to increased sensitivity of factor IX activity to phenprocoumon therapy. Ann Hematol 74(6):265–268

    Article  PubMed  CAS  Google Scholar 

  16. Ulrich S, Brand B, Speich R, Oldenburg J, Asmis L (2008) Congenital hypersensitivity to vitamin K antagonists due to FIX propeptide mutation at locus -10: a (not so) rare cause of bleeding under oral anticoagulant therapy in Switzerland. Swiss Med Wkly 138(7–8):100–107

    PubMed  CAS  Google Scholar 

  17. Bestmann L, Zuger M, Oldenburg J, Buhler D, Maly FE (2001) Coagulation factor IX propeptide mutations causing coumarin hypersensitivity: identification of female alanine-10 valine heterozygotes. Thromb Haemost 85(3):567–568

    PubMed  CAS  Google Scholar 

  18. Peters J, Luddington R, Brown K, Baglin C, Baglin T (1997) Should patients starting anticoagulant therapy be screened for missense mutations at Ala-10 in the factor IX propeptide? Br J Haematol 99(2):467–468

    PubMed  CAS  Google Scholar 

  19. Tassies D, Monteagudo J, Maragall S, Ordinas A, Reverter JC (2005) No impact of factor IX Ala-10 mutations in acenocoumarol-treated southern Europeans. Blood Coagul Fibrinolysis 16(8):563–566

    Article  PubMed  CAS  Google Scholar 

  20. van der Meer FJ, Vos HL, Rosendaal FR (1999) No indication for APTT screening in patients on oral anticoagulant therapy. Thromb Haemost 81(3):364–366

    PubMed  Google Scholar 

Download references

Acknowledgments

We thank Drs. M. Wicki, B. Portmann and Zimerli for participating in the screening part of the study.

Author information

Authors and Affiliations

  1. Service and Central Laboratory of Hematology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, rue du Bugnon 46, CH-1011, Lausanne, Switzerland

    Mathilde Gavillet, Claire Abbal, Jasmine Nötzli, Jean-François Lambert & Anne Angelillo-Scherrer

  2. Department of Radiology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, rue du Bugnon 46, CH-1011, Lausanne, Switzerland

    Sabine Schmidt

Authors
  1. Mathilde Gavillet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claire Abbal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sabine Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jasmine Nötzli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jean-François Lambert
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anne Angelillo-Scherrer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anne Angelillo-Scherrer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gavillet, M., Abbal, C., Schmidt, S. et al. Life-threatening bleeding under vitamin K antagonists in spite of an INR in the therapeutic range. J Thromb Thrombolysis 32, 232–237 (2011). https://doi.org/10.1007/s11239-011-0580-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-011-0580-y

Keywords

Search

Navigation